Aminoglycosides: Difference between revisions

From IDWiki
m ()
(: added Hartford nomo)
Line 47: Line 47:
=== Hartford Nomogram ===
=== Hartford Nomogram ===


[[File:Hartford_nomogram.png]]
![](Hartford nomogram.png)


== Origin ==
== Origin ==

Revision as of 15:11, 16 December 2019

Dosing

Initial

If actual body weight more than 20% higher than ideal body weight, need to calculate adjusted body weight (ABW)

$$ABW = IBW + 0.4 \times (actual BW - IBW)$$

Traditional q8h dosing

  • Used for Enterococcus IE, meningitis, septic shock, ascites, AKI/CKD, prefnancy, surgical prophylaxis, burns, osteomyelitis
  • 1.7mg/kg (5-7.5mg/kg amikacin)

Extended interval dosing

  • 7mg/kg (15mg/kg amikacin)
  • Use Hartford nomogram with a random level (but remember to halve the amikacin level first)
  • CrCl ≥60 q24h
  • CrCl 40-59 q36h
  • CrCl 20-39 q48h
  • CrCl ≤19 don't use

Dialysis

  • Pre-HD levels with post-HD doses, though this may change

Synergy

  • 1mg/kg divided q8-12h, peak target 3-5, trough <2

Monitoring

Peak

  • 30min after third? dose
  • Response is based on peak:MIC ratio, target is 8-10 times
  • If below target, increase dose

Trough

  • Prior to 4th dose, or a random level at 24-48h in renal failure
  • Side effects are predicted by trough levels
  • Tobra <0.5 (extended) or <2 (traditional)
  • Amikacin <1 (extended) or <?? (traditional)
  • If above target, increase interval

Hartford Nomogram

Hartford nomogram.png

Origin

Mechanism

  • Requires electron transport chain (ETC) to cross over the membrane
    • Anaerobes are therefore inherently resistant
  • Reversibly binds 30S ribosomal subunit, which stops proofreading and causes accumulation of bad proteins

Spectrum of Activity

  • Good coverage of Gram-negative aerobes
    • Except Stenotrophomonas and Burkholderia
  • Streptomycin also covers mycobacterium
  • Some protozoal coverage
  • Can cover Gram-positives if cell wall is disrupted (e.g. by beta-lactam)

Resistance

  • Altered 50S ribosomal subunit
  • Decreased uptake and accumulation (Pseudomonas)
  • Decreased membrane permeability
  • Efflux (E. coli)
  • Aminoglycoside-modifying enzymes (Enterococcus)

PK/PD

  • Poor membrane penetration, therefore doesn't cross over into lungs and CSF
  • Half-life 2-3 hours (longer in CKD)
  • Excreted 99% unchanged in urine
  • Displays concentration-depedent killing with a prolonged post-antibiotic effect (2-13 hours)

Side Effects

  • Nephrotoxicity (0-50%), usually non-oliguric AKI with decreased Ca/Mg resorption, often reversible
    • Decreased protein synthesis
    • Decreased cellular respiration
    • Increased apoptosis
    • Necrosis in proximal tubules
  • Ototoxicity (0-60%), irreversible
    • Cumulative effect
    • Distribute into the perilymph of the ear, and cause free radical formation causing apoptosis of hair cells
    • Needs hearing tests, because it can be subclinical
      • Monitor audiometry weekly
  • Vestibulotoxicity (0-20%), irreversible
  • Rarely, neuromuscular blockade

Monitoring

  • Trough levels
  • Creatinine
  • Weekly audiometry